Moderna, Inc. Contracts & Agreements

Amended and Restated Executive Severance Plan and Form of Participation Letter, as amended on February (Filed With SEC on February 24, 2023)

Offer Letter by and between ModernaTX, Inc. and Arpa Garay, dated as of April 21, 2022 (Filed With SEC on February 24, 2023)

Amended and Restated Non-Employee Director Compensation Policy, effective October 1, 2022 (Filed With SEC on November 3, 2022)

Offer Letter by and between ModernaTX, Inc. and James Mock, dated as of August 15, 2022 (Filed With SEC on November 3, 2022)

Amendment No. PZ0025 and P00026 to Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of Defense, dated... (Filed With SEC on November 3, 2022)

Amended and Restated Non-Employee Director Compensation Policy, effective April 28, 2022 (Filed With SEC on August 3, 2022)

Amendment No. 13 to Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as of March 23, 2022 (Filed With SEC on August 3, 2022)

Amendment No. P00024 to Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of Defense, dated August 9, 2020 (Filed With SEC on August 3, 2022)

Updated Executive Retirement and Strategic Consulting Agreement, dated May 27, 2022, between ModernaTX, Inc. and David Meline (Filed With SEC on June 1, 2022)

Executive Separation Agreement and Release, dated May 13, 2022, between ModernaTX, Inc. and Jorge Gomez (Filed With SEC on May 13, 2022)

Offer Letter by and between ModernaTX, Inc. and Jorge Gomez, dated as of April 6, 2022 (Filed With SEC on May 4, 2022)

Executive Retirement and Strategic Consulting Agreement by and between ModernaTX, Inc. and David Meline, dated as of April (Filed With SEC on May 4, 2022)

Amendment No. 12 to Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as of March 23, 2022 (Filed With SEC on May 4, 2022)

Amendment Nos. P00022 and P00023 to Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of Defense, dated... (Filed With SEC on May 4, 2022)

Third Amendment, dated September 11, 2018, Fourth Amendment, dated March 28, 2019, and Omnibus Amendment, dated December 30, 2021, to Net Lease, dated as of August 29, 2016, as... (Filed With SEC on February 25, 2022)

Offer Letter by and between ModernaTX, Inc. and Corin (Filed With SEC on February 25, 2022)

Executive Separation and Transitional Services Agreement (Filed With SEC on February 25, 2022)

Consulting Agreement by and between ModernaTX, Inc. and Corinne Le Goff (Filed With SEC on February 25, 2022)

Employment Letter Agreement between ModernaTX, Inc. and Shannon Klinger, dated as of March 4, 2021 (Filed With SEC on February 25, 2022)

Form of Employee Restricted Stock Unit Award Agreement (Filed With SEC on February 25, 2022)

Form of Employee Non-Qualified Stock Option Agreement (Filed With SEC on February 25, 2022)

Form of Non-Employee Director Restricted Stock Unit Award Agreement (Filed With SEC on February 25, 2022)

Form of Non-Employee Director Non-Qualified Stock Option Agreement (Filed With SEC on February 25, 2022)

Amendment No. 11 to Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as of November 4, 2021 (Filed With SEC on February 25, 2022)

Amendment Nos. P00018, P00019, P00020, and P00021 to Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of... (Filed With SEC on February 25, 2022)

Amendment Nos. P00012, P00013, P00014, P00015, P00016 and P00017 to Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S.... (Filed With SEC on November 4, 2021)

Amendment No (Filed With SEC on November 4, 2021)

Amendment No. 6, dated February 16, 2021 (Filed With SEC on May 6, 2021)

Amendment No. 7, dated March 12, 2021, to Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as... (Filed With SEC on May 6, 2021)

Form of Performance-Based Restricted Stock Unit Award Agreement under the 2018 Stock Option and Incentive Plan (Filed With SEC on May 6, 2021)

Amended and Restated Non-Employee Director Compensation Policy, effective April 28, 2021 (Filed With SEC on May 6, 2021)

Description of Capital Stock (Filed With SEC on February 26, 2021)

Amended and Restated Executive Retention Agreement by and between the Company and Tal Zaks, dated as of February 23, 2021 (Filed With SEC on February 26, 2021)

Amendment No. P00003 to Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of Defense, dated December 11, 2020 (Filed With SEC on February 26, 2021)

Agreement No. HHSO100201600029C, by and between the Company and the Biomedical Advanced Research and Development Authority, dated as of April 16, 2020, as amended on May 24, 2020,... (Filed With SEC on October 30, 2020)

Global Long Term Agreement, by and among ModernaTX Inc., Lonza Sales Ltd., and Lonza Ltd., dated September 4, 2020 (Filed With SEC on October 30, 2020)

Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of Defense, dated August 9, 2020, as amended September 8,... (Filed With SEC on October 30, 2020)

Agreement No. HHSO100201600029C, by and between the Company and the Biomedical Advanced Research and Development Authority, dated as of April 16, 2020, as amended (Filed With SEC on August 6, 2020)

Offer Letter by and between the Company and David W. Meline, dated as of June 3, 2020 (Filed With SEC on August 6, 2020)

Underwriting Agreement, dated as of May 18, 2020, by and between Moderna, Inc. and Morgan Stanley & Co. LLC (Filed With SEC on May 20, 2020)

Executive Retention and Separation Agreement, dated May 5, 2020, by and between Moderna, Inc. and Lorence Kim, M.D (Filed With SEC on May 7, 2020)

Executive Retention Agreement, dated March 29, 2020, by and between Moderna, Inc. and Tal Zaks, M.D (Filed With SEC on March 30, 2020)

Description of Capital Stock (Filed With SEC on February 27, 2020)

Offer Letter by and between the Company and Tal Zaks, dated as of February 17, 2015 (Filed With SEC on February 27, 2020)

Offer Letter by and between the Company and Juan Andres, dated as of March 16, 2017 (Filed With SEC on February 27, 2020)

Underwriting Agreement, dated as of February 11, 2020, by and among Moderna, Inc. and Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC, as representatives of the underwriters (Filed With SEC on February 12, 2020)

Fifth Amendment to Lease, by and between ModernaTx, Inc. and ARE-Tech Square, LLC dated as of August 28, 2019 (Filed With SEC on November 6, 2019)

Fifth Amendment to Collaboration and License Agreement by and between ModernaTX, Inc. and Merck Sharp & Dohme Corp., dated as of May 3, 2019 (Filed With SEC on August 8, 2019)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 9, 2019)

Strategic Advisor & Transition Agreement by and between ModernaTX, Inc. and John Mendlein, dated as of January 17, 2019 (Filed With SEC on March 13, 2019)

Form of Underwriting Agreement (Filed With SEC on November 28, 2018)

Form of Non-Plan Restricted Stock Award Agreement (Filed With SEC on November 28, 2018)

Form of Non-Plan Non-Qualified Stock Option Agreement (Filed With SEC on November 28, 2018)

Specimen Common Stock Certificate (Filed With SEC on November 9, 2018)

Second Amended and Restated Investors Rights Agreement by and among the Registrant and certain of its stockholders, dated May 7, 2018 (Filed With SEC on November 9, 2018)

2016 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder (Filed With SEC on November 9, 2018)

2018 Stock Option and Incentive Plan and forms of award agreements thereunder (Filed With SEC on November 9, 2018)

Form of Indemnification Agreement between the Registrant and each of its directors (Filed With SEC on November 9, 2018)

Master Collaboration and License Agreement, by and between Moderna Therapeutics, Inc. and Merck Sharp & Dohme Corp., dated as of January 12, 2015, as amended by Amendment No. 1... (Filed With SEC on November 9, 2018)